EYE » Topics » Refractive sales rose 1.5% to $118.3 million.
This excerpt taken from the EYE 8-K filed Aug 4, 2008.
Refractive sales rose 1.5% to $118.3 million.
Procedures, implants and related sales were $77.4 million, down slightly from $78.1 million one year ago as U.S. excimer
and refractive IOL market weakness was mostly offset by increased global penetration of the companys IntraLase®technology and international growth of its refractive procedures
AMOs U.S. excimer procedure volumes declined approximately 20% in the second quarter and approximately 6% for the trailing 12 months ended June 27, 2008.
For the trailing 12 months ended June 27, 2008, the companys U.S. custom mix was 67%; the second-quarter custom mix was 68%, compared to 65% in the year-ago quarter.
AMOs U.S. femtosecond procedure volumes grew approximately 14% in the second quarter and approximately 25% for the trailing 12 months ended June 27,
2008, on a pro forma basis.
AMOs international procedure, implant and related sales hit a new high in the second quarter, at $31.6 million, up 45.1%.
System sales rose 10.1% to $31.3 million, reflecting the continued demand for the companys iLASIKTM platform worldwide.
Bet you've never seen portfolio analytics like these.